See more : Barry Callebaut AG (BYCBF) Income Statement Analysis – Financial Results
Complete financial analysis of PaxMedica, Inc. Common Stock (PXMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PaxMedica, Inc. Common Stock, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- S&P Syndicate Public Company Limited (SNP.BK) Income Statement Analysis – Financial Results
- Century Extrusions Limited (CENTEXT.NS) Income Statement Analysis – Financial Results
- Volution Group plc (VLUTF) Income Statement Analysis – Financial Results
- Energisa Mato Grosso – Distribuidora de Energia S/A (ENMT3.SA) Income Statement Analysis – Financial Results
- R J BIO-TECH LTD (RJBIOTECH.BO) Income Statement Analysis – Financial Results
PaxMedica, Inc. Common Stock (PXMD)
About PaxMedica, Inc. Common Stock
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis. It is also involved in developing PAX-102, an intranasal formulation of suramin for neurologic indications. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York. PaxMedica, Inc. operates as a subsidiary of Tardimed Sciences LLC.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 3.91M | 1.79M | 2.22M | 936.78K | 484.11K |
| General & Administrative | 12.23B | 8.82M | 4.97M | 4.63M | 114.50K |
| Selling & Marketing | -12.22B | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 12.23M | 8.82M | 4.97M | 4.63M | 114.50K |
| Other Expenses | 0.00 | -5.51M | 173.35K | -53.54K | 0.00 |
| Operating Expenses | 16.15M | 10.60M | 7.20M | 5.57M | 598.61K |
| Cost & Expenses | 16.15M | 10.60M | 7.20M | 5.57M | 598.61K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 9.17K | 5.24K | 2.81M | 609.46K | 0.00 |
| Depreciation & Amortization | 167.90K | -5.90M | 173.35K | -53.54K | 171.86K |
| EBITDA | -16.15M | -10.60M | -7.20M | -5.62M | -598.61K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -16.15M | -10.60M | -7.20M | -5.57M | -598.61K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.14M | -4.20M | -3.03M | -2.26M | 0.00 |
| Income Before Tax | -18.29M | -14.80M | -10.23M | -7.83M | -598.61K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -167.90K | 4.19M | 2.81M | 663.00K | -171.86K |
| Net Income | -18.29M | -14.80M | -13.03M | -8.49M | -598.61K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -11.00 | -28.79 | -18.81 | -12.25 | -0.06 |
| EPS Diluted | -11.00 | -28.79 | -18.81 | -12.25 | -0.06 |
| Weighted Avg Shares Out | 1.66M | 514.22K | 692.91K | 692.91K | 10.02M |
| Weighted Avg Shares Out (Dil) | 1.66M | 514.22K | 692.91K | 692.91K | 10.02M |
Why Is PaxMedica (PXMD) Stock Up 95% Today?
PaxMedica (NASDAQ: PXMD ) stock is rising higher on Tuesday as investors celebrate the company's publication of Phase 2 clinical trial results. The study was published in the Annals of General Psychiatry and focused on the use of low-dose suramin...
Penny Stocks To Buy Now? 3 to Watch With Big News
Let's talk penny stocks, those under-five-dollar shares that buzz with potential. They're nimble, sensitive to the slightest news, and can pivot on a dime.
PaxMedica Announces Publication of Its Autism Spectrum Disorder Phase 2 Study Results in Peer-reviewed Journal
TARRYTOWN, NY / ACCESSWIRE / November 7, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, announced the publication of research findings in the Annals of General Psychiatry. The research, led by Chief Medical...
PaxMedica Engages Bourne Partners to Explore Future Monetization of Potential Priority Review Voucher (PRV)
TARRYTOWN, N.Y., Nov. 02, 2023 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (Nasdaq: PXMD ), a pioneering biopharmaceutical company focused on advancing treatments for neurologic disorders, has engaged Bourne Partners , a leading financial services firm specializing in the...
PaxMedica Acquires Suramin Research Assets from Rediscovery Life Sciences to Accelerate NDA Submission for PAX-101
TARRYTOWN, New York, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica , Inc. (Nasdaq: PXMD ), a pioneering biopharmaceutical company specializing in cutting-edge treatments for neurological disorders, announced today the successful acquisition of certain suramin research assets from...
PaxMedica Announces 1-for-17 Reverse Stock Split
TARRYTOWN, N.Y. , Oct. 30, 2023 (GLOBE NEWSWIRE) -- via IBN — PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD) and other serious...
Why Is PaxMedica (PXMD) Stock Up Today?
PaxMedica (NASDAQ: PXMD ) stock is jumping significantly higher against the backdrop of another soft session on Wall Street. This morning, management announced a productive discussion with the U.S. Food and Drug Administration (FDA) over positive clinical trial results for...
PaxMedica's Research on Low Dose Suramin for Autism Spectrum Disorder Accepted for Publication
TARRYTOWN, N.Y. , Oct. 26, 2023 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica , Inc. (Nasdaq: PXMD ) a clinical-stage biopharmaceutical company, is excited to announce that the Annals of General Psychiatry, an internationally recognized scientific psychiatry publication, has accepted...
Best Penny Stocks To Buy Now? 4 Biotech Stocks To Watch
If you're wondering what is going on in the stock market today or which penny stocks to buy now that major indexes are lower, you're not alone. Earnings season mixed with economic data has resulted in a sharp downturn for...
PaxMedica to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Presentation on Tuesday, September 12, 2023 at 3:00pm EDT TARRYTOWN, NY, Aug. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for...
Source: https://incomestatements.info
Category: Stock Reports